AFFY:OTC-Affymax, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.03

Change

0.00 (0.00)%

Market Cap

USD 2.94M

Volume

4.23K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-1.19 (-1.73%)

USD162.57B 24.98 2.76
CSLLY CSL Limited

+0.81 (+0.78%)

USD94.29B 42.48 24.49
CMXHF CSL Limited

N/A

USD94.17B 42.37 24.49
GNMSF Genmab A/S

+2.56 (+0.73%)

USD23.24B 28.18 3.06
UCBJF UCB SA

N/A

USD22.12B 24.73 18.77
UCBJY UCB SA

-0.67 (-1.15%)

USD21.92B 24.83 18.77
SBHMY Sino Biopharmaceutical Limited

+1.76 (+8.80%)

USD21.14B 47.10 3.58
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.95B 52.75 3.58
PPTDF PeptiDream Inc

N/A

USD5.30B 260.99 1.36
MPSYF MorphoSys AG

N/A

USD4.23B 32.27 28.84

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.33% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 30.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -66.67% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.67% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.34% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.34% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.97% N/A N/A N/A N/A
Risk Adjusted Return -23.75% N/A N/A N/A N/A
Market Capitalization 2.94M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.96 N/A N/A N/A N/A
Price/Book Ratio 0.56 N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 111.59% N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets -228.91% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.35 N/A N/A N/A N/A
Short Percent 49.35% N/A N/A N/A N/A
Beta 2.39 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike